1. EHF is a novel regulator of cellular redox metabolism and predicts patient prognosis in HNSCC
   Akinsola Oyelakin et al, 2022, NAR Cancer CrossRef
2. Identification of novel activators of the metal responsive transcription factor (MTF-1) using a gene expression biomarker in a microarray compendium
   Abigail C Jackson et al, 2020, Metallomics CrossRef
3. Latent Kaposi’s sarcoma-associated herpesvirus infection in bladder cancer cells promotes drug resistance by reducing reactive oxygen species
   Suhyuk Lee et al, 2016, Journal of Microbiology CrossRef
4. Molecular Dissection of Induced Platinum Resistance through Functional and Gene Expression Analysis in a Cell Culture Model of Bladder Cancer
   Sisi Wang et al, 2016, PLOS ONE CrossRef
5. Aldo-keto reductase 1C1 induced by interleukin-1β mediates the invasive potential and drug resistance of metastatic bladder cancer cells
   Ryuji Matsumoto et al, 2016, Scientific Reports CrossRef
6. Comparative proteomics analysis of whey fractions from Korean mother's milk with different gender babies in the northeast China
   Boxue Xia et al, 2024, International Journal of Dairy Technology CrossRef
7. SILAC‐based quantitative proteomic analysis reveals widespread molecular alterations in human skin keratinocytes upon chronic arsenic exposure
   Sartaj Ahmad Mir et al, 2017, PROTEOMICS CrossRef
8. Analysis of the mechanism of aldo-keto reductase dependent cis-platin resistance in HepG2 cells based on transcriptomic and NADH metabolic state
   TINGTING SUN et al, 2023, BIOCELL CrossRef
9. VEGF-C inhibition reverses resistance of bladder cancer cells to cisplatin via upregulating maspin
   HAIPENG ZHU et al, 2015, Molecular Medicine Reports CrossRef
10. Drug-induced oxidative stress in cancer treatments: Angel or devil?
    Hao Jiang et al, 2023, Redox Biology CrossRef
11. Aberrant expression of claudin‐6 contributes to malignant potentials and drug resistance of cervical adenocarcinoma
    Yui Ito et al, 2022, Cancer Science CrossRef
12. The effect of the alpha-specific PI3K inhibitor alpelisib combined with anti-HER2 therapy in HER2+/PIK3CA mutant breast cancer
    Maria Letizia Cataldo et al, 2023, Frontiers in Oncology CrossRef
13. Integrated data analysis reveals significant associations of KEAP1 mutations with DNA methylation alterations in lung adenocarcinomas
    Mohamed Elshaer et al, 2020, Aging CrossRef
14. Transcriptomic insights into the zinc homeostasis of MCF-7 breast cancer cells via next-generation RNA sequencing
    Mohammad S Zaman et al, 2021, Metallomics CrossRef
15. Elucidating Role of Reactive Oxygen Species (ROS) in Cisplatin Chemotherapy: A Focus on Molecular Pathways and Possible Therapeutic Strategies
    Sepideh Mirzaei et al, 2021, Molecules CrossRef
16. Label-Free Quantitative Proteomics Analysis of the Sorafenib Resistance in HepG2 Cells
    Zi-Xuan Wang et al, 2022, Journal of Analysis and Testing CrossRef
17. AKR1C2 acts as a targetable oncogene in esophageal squamous cell carcinoma via activating PI3K/AKT signaling pathway
    Zhan‐Fei Zhang et al, 2020, Journal of Cellular and Molecular Medicine CrossRef
18. Investigation of the Potential of Bile Acid Methyl Esters as Inhibitors of Aldo‐keto Reductase 1C2: Insight from Molecular Docking, Virtual Screening, Experimental Assays and Molecular Dynamics
    Maja A. Marinović et al, 2022, Molecular Informatics CrossRef
19. Emodin mitigates the oxidative stress induced by cisplatin in osteosarcoma MG63 cells
    Li Yan et al, 2016, Oncology Letters CrossRef
20. Inhibition of IGFBP-2 improves the sensitivity of bladder cancer cells to cisplatin via upregulating the expression of maspin
    HAIPENG ZHU et al, 2015, International Journal of Molecular Medicine CrossRef
21. Cisplatin-Resistant Urothelial Bladder Cancer Cells Undergo Metabolic Reprogramming beyond the Warburg Effect
    Julieta Afonso et al, 2024, Cancers CrossRef